CN112587670B - 一种靶向调控白色脂肪棕色化的dna纳米花药物制备方法 - Google Patents
一种靶向调控白色脂肪棕色化的dna纳米花药物制备方法 Download PDFInfo
- Publication number
- CN112587670B CN112587670B CN202110227528.2A CN202110227528A CN112587670B CN 112587670 B CN112587670 B CN 112587670B CN 202110227528 A CN202110227528 A CN 202110227528A CN 112587670 B CN112587670 B CN 112587670B
- Authority
- CN
- China
- Prior art keywords
- dna
- nanoflower
- allicin
- adipocyte
- targeted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002057 nanoflower Substances 0.000 title claims abstract description 133
- 239000003814 drug Substances 0.000 title claims abstract description 74
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 210000000593 adipose tissue white Anatomy 0.000 title abstract description 13
- 230000033228 biological regulation Effects 0.000 title abstract description 9
- 108020004414 DNA Proteins 0.000 claims abstract description 183
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 claims abstract description 75
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 claims abstract description 74
- 235000010081 allicin Nutrition 0.000 claims abstract description 74
- 229940079593 drug Drugs 0.000 claims abstract description 60
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 50
- 238000011068 loading method Methods 0.000 claims abstract description 23
- 230000008685 targeting Effects 0.000 claims abstract description 22
- 230000037149 energy metabolism Effects 0.000 claims abstract description 17
- 108091023037 Aptamer Proteins 0.000 claims abstract description 14
- 230000001105 regulatory effect Effects 0.000 claims abstract description 8
- 230000003321 amplification Effects 0.000 claims description 26
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 26
- 238000005096 rolling process Methods 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 238000006116 polymerization reaction Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 10
- 102000012410 DNA Ligases Human genes 0.000 claims description 8
- 108010061982 DNA Ligases Proteins 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 239000007853 buffer solution Substances 0.000 claims description 7
- 238000009739 binding Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 5
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 4
- 238000000137 annealing Methods 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 108091008102 DNA aptamers Proteins 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 abstract description 14
- 235000020824 obesity Nutrition 0.000 abstract description 14
- 150000007523 nucleic acids Chemical class 0.000 abstract description 7
- 108020004707 nucleic acids Proteins 0.000 abstract description 5
- 102000039446 nucleic acids Human genes 0.000 abstract description 5
- 102000053602 DNA Human genes 0.000 abstract description 3
- 230000001276 controlling effect Effects 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 abstract description 3
- 230000003993 interaction Effects 0.000 abstract description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 21
- 230000000694 effects Effects 0.000 description 12
- 230000004069 differentiation Effects 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 101710163270 Nuclease Proteins 0.000 description 6
- 210000003486 adipose tissue brown Anatomy 0.000 description 6
- 230000003579 anti-obesity Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 5
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 210000000229 preadipocyte Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102100024853 Carnitine O-palmitoyltransferase 2, mitochondrial Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000859570 Homo sapiens Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 3
- 101000909313 Homo sapiens Carnitine O-palmitoyltransferase 2, mitochondrial Proteins 0.000 description 3
- 101000989606 Homo sapiens Cholinephosphotransferase 1 Proteins 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 210000001700 mitochondrial membrane Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000013116 obese mouse model Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 2
- 238000011814 C57BL/6N mouse Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000017946 PGC-1 Human genes 0.000 description 2
- 108700038399 PGC-1 Proteins 0.000 description 2
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000001593 brown adipocyte Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- PUIBPGHAXSCVRF-QHFGJBOXSA-N prostaglandin C1 Chemical compound CCCCC[C@H](O)\C=C\C1=CCC(=O)[C@@H]1CCCCCCC(O)=O PUIBPGHAXSCVRF-QHFGJBOXSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000035924 thermogenesis Effects 0.000 description 2
- 230000000476 thermogenic effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- ADRPZEYTIFWCBC-UHFFFAOYSA-N 2-fluoro-n-methyl-n-naphthalen-1-ylacetamide Chemical compound C1=CC=C2C(N(C(=O)CF)C)=CC=CC2=C1 ADRPZEYTIFWCBC-UHFFFAOYSA-N 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 101150011389 Chpt1 gene Proteins 0.000 description 1
- 101150073133 Cpt1a gene Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001046599 Homo sapiens Krueppel-like factor 15 Proteins 0.000 description 1
- 102100022328 Krueppel-like factor 15 Human genes 0.000 description 1
- 102100029820 Mitochondrial brown fat uncoupling protein 1 Human genes 0.000 description 1
- 108050002686 Mitochondrial brown fat uncoupling protein 1 Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101150104557 Ppargc1a gene Proteins 0.000 description 1
- 101150101356 Ppargc1b gene Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 101150022052 UCP1 gene Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 244000245420 ail Species 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002059 nanofabric Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000000636 white adipocyte Anatomy 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Manufacturing & Machinery (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110227528.2A CN112587670B (zh) | 2021-03-02 | 2021-03-02 | 一种靶向调控白色脂肪棕色化的dna纳米花药物制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110227528.2A CN112587670B (zh) | 2021-03-02 | 2021-03-02 | 一种靶向调控白色脂肪棕色化的dna纳米花药物制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112587670A CN112587670A (zh) | 2021-04-02 |
CN112587670B true CN112587670B (zh) | 2021-05-11 |
Family
ID=75207776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110227528.2A Active CN112587670B (zh) | 2021-03-02 | 2021-03-02 | 一种靶向调控白色脂肪棕色化的dna纳米花药物制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112587670B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113975397B (zh) * | 2021-10-26 | 2023-08-22 | 中南大学湘雅三医院 | 一种基因/小分子化合物纳米递药系统及其制备方法与应用 |
CN114246951A (zh) * | 2021-12-24 | 2022-03-29 | 中国石油大学(华东) | 一种dna纳米载体复合物及其制备方法和应用 |
CN114767660B (zh) * | 2022-06-22 | 2022-09-02 | 中国农业大学 | 一种靶向协同降脂的纳米双药制备及应用 |
CN115813860A (zh) * | 2022-12-10 | 2023-03-21 | 郑州大学 | 一种超小型可编程纯核酸纳米粒的制备方法及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010063998A2 (en) * | 2008-12-01 | 2010-06-10 | Isis Innovation Limited | Antibiotic nanomaterial |
CN110507818A (zh) * | 2018-05-21 | 2019-11-29 | 国家纳米科学中心 | 一种dna纳米花形复合结构及其制备方法和应用 |
CN111249468A (zh) * | 2020-03-18 | 2020-06-09 | 湖南大学 | 一种脂肪细胞靶向的dna纳米药物及其制备方法与应用 |
-
2021
- 2021-03-02 CN CN202110227528.2A patent/CN112587670B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010063998A2 (en) * | 2008-12-01 | 2010-06-10 | Isis Innovation Limited | Antibiotic nanomaterial |
CN110507818A (zh) * | 2018-05-21 | 2019-11-29 | 国家纳米科学中心 | 一种dna纳米花形复合结构及其制备方法和应用 |
CN111249468A (zh) * | 2020-03-18 | 2020-06-09 | 湖南大学 | 一种脂肪细胞靶向的dna纳米药物及其制备方法与应用 |
Non-Patent Citations (3)
Title |
---|
"Allicin Regulates Energy Homeostasis through Brown Adipose Tissue";Chuanhai Zhang et al.;《iScience》;20200522;第23卷(第5期);第101113-101144页 * |
"Green synthesis of allicin based hybrid nanoflowers with evaluation of their catalytic and antimicrobial activities";Fatih Dogan Koca et al.;《Biotechnol Lett》;20200402;第42卷;第1683-1690页 * |
Chuanhai Zhang et al.."Allicin Regulates Energy Homeostasis through Brown Adipose Tissue".《iScience》.2020,第23卷(第5期),第101113-101144页. * |
Also Published As
Publication number | Publication date |
---|---|
CN112587670A (zh) | 2021-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112587670B (zh) | 一种靶向调控白色脂肪棕色化的dna纳米花药物制备方法 | |
Abrahamse | Regenerative medicine, stem cells, and low-level laser therapy: future directives | |
US20150291962A1 (en) | Extraction, preparation, and application of plant micro-ribonucleic acid | |
CN109715197A (zh) | 胶原水解产物用于改善耐力表现和刺激脂质分解代谢的用途 | |
CN101926459A (zh) | 一种能提升学习记忆力预防考试焦虑的制剂及制备方法 | |
CN112587542B (zh) | Dna四面体在制备治疗肾损伤的药物中的用途 | |
CN101862446A (zh) | Sod葡萄保健酒 | |
Liu et al. | An all-in-one nanoplatform with near-infrared light promoted on-demand oxygen release and deep intratumoral penetration for synergistic photothermal/photodynamic therapy | |
CN101084925B (zh) | 一种鹿茸母液的生产工艺 | |
Chen et al. | Application of programmable tetrahedral framework nucleic acid-based nanomaterials in neurological disorders: Progress and prospects | |
KR20170129281A (ko) | 혈소판 유래 성장 인자-bb 생성 항진제, 및 그것을 포함하는 간엽계 줄기세포 생성 촉진제, 줄기세포 안정화제, 및 진피 재생화제 | |
CN111249468B (zh) | 一种脂肪细胞靶向的dna纳米药物及其制备方法与应用 | |
WO2020004014A1 (ja) | エルゴチオネイン、アスコルビン酸2-グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用 | |
DK3140396T3 (en) | Procedure for the expansion of adult stem cells from whole blood | |
AU2012354703B2 (en) | Hydroxymethylfurfural derivative | |
CN107951825A (zh) | 一种含有枸杞干细胞提取物的祛斑护肤品及其制备方法 | |
TW201303020A (zh) | 血小板衍生成長因子(pdgf)-bb產生亢進劑、及含有其之幹細胞穩定劑 | |
CN114767660B (zh) | 一种靶向协同降脂的纳米双药制备及应用 | |
JP2019529365A (ja) | 持久運動能力を向上させるためおよび脂質代謝を刺激するためのコラーゲン加水分解物の使用 | |
CN102973513B (zh) | 智能纳米药物传递系统和制备方法及应用 | |
CN112843082B (zh) | Dna四面体在制备治疗糖尿病的药物中的用途 | |
TWI740536B (zh) | 平臥菊三七萃取物用於製備改善睡眠品質的組合物之用途 | |
CN115778978A (zh) | 一种dna和rna杂化纳米花的制备方法及其应用 | |
CN116421713A (zh) | 一种抗衰老组合物及其应用 | |
CN114601934A (zh) | 负载小干扰rna的可电荷反转光热纳米粒子及其制备和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220406 Address after: 231200 5th floor, b-13a, industrial investment Liheng industrial Plaza, bustling Avenue, Taohua Industrial Park, economic development zone, Hefei, Anhui Province Patentee after: ANHUI CAPA BIO-TECH CO.,LTD. Address before: 100083 No. 2 Old Summer Palace West Road, Beijing, Haidian District Patentee before: CHINA AGRICULTURAL University |
|
TR01 | Transfer of patent right |
Effective date of registration: 20240506 Address after: 232221 Southeast side of the intersection of Xingye Avenue and Huanglou Road in Xinqiao International Industrial Park, Shouxian County, Huainan City, Anhui Province Patentee after: Anhui Jiaweike Biotechnology Co.,Ltd. Country or region after: China Address before: 231200 5th floor, b-13a, industrial investment Liheng industrial Plaza, bustling Avenue, Taohua Industrial Park, economic development zone, Hefei, Anhui Province Patentee before: ANHUI CAPA BIO-TECH CO.,LTD. Country or region before: China |